The Maryland chapter of the Pulmonary Hypertension Association (PHA) recently announced that it is hosting a presentation on Emergency Preparedness for Pulmonary Hypertension Patients, via their Facebook page, which is taking place on Tuesday, September 23rd at 10 pm. The event is designed to help educated patients on the disease, with the presence of Dr. Amy Sisk, RPh.
The PHA supports groups in 49 states, Puerto Rico and the District of Columbia with the purpose of finding ways of preventing and curing pulmonary hypertension, as well as providing hope, support, education, research, advocacy, and awareness to patients and families. The nonprofit organization serves more than 13,000 members and supporters and works to end isolation, to provide education, and to involve its constituents into finding a cure for the disease.
The event is being sponsored by Gilead Sciences, a biopharmaceutical company dedicated to research, development and commercialization of innovative treatments for unmet medical needs. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions. The company recently announced positive results of its AMBrIsentan and Tadalafil in patients with pulmonary arterial hypertension phase 3 clinical trial.